Market Closed -
Nasdaq
21:00:00 17/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.685
USD
|
-2.88%
|
|
-2.03%
|
-44.02%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
70.36
|
64.53
|
73.45
|
68.14
|
43.15
|
-
|
-
|
Enterprise Value (EV)
1 |
70.36
|
64.53
|
73.45
|
68.14
|
43.15
|
43.15
|
43.15
|
P/E ratio
|
-
|
-0.98
x
|
4.06
x
|
-6.54
x
|
-5.91
x
|
0.94
x
|
0.57
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
110
x
|
1.84
x
|
3.58
x
|
1.99
x
|
0.65
x
|
0.38
x
|
EV / Revenue
|
-
|
110
x
|
1.84
x
|
3.58
x
|
1.99
x
|
0.65
x
|
0.38
x
|
EV / EBITDA
|
-
|
-3,104,382
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-3.33
x
|
-
|
-61.3
x
|
-2.17
x
|
-3.55
x
|
5.04
x
|
FCF Yield
|
-
|
-30%
|
-
|
-1.63%
|
-46%
|
-28.1%
|
19.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,842
|
17,300
|
20,807
|
22,638
|
25,609
|
-
|
-
|
Reference price
2 |
6.490
|
3.730
|
3.530
|
3.010
|
1.685
|
1.685
|
1.685
|
Announcement Date
|
11/03/21
|
24/03/22
|
30/03/23
|
08/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.589
|
39.85
|
19.05
|
21.71
|
66.38
|
112.5
|
EBITDA
|
-
|
-
|
-20.79
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-19.97
|
-22.7
|
18.23
|
-10.56
|
-11.73
|
24.27
|
63.02
|
Operating Margin
|
-
|
-
|
-3,854.84%
|
45.74%
|
-55.45%
|
-54.03%
|
36.56%
|
56.03%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-56.69
|
18.2
|
-9.974
|
-7.172
|
44.21
|
92.76
|
Net income
1 |
-6.169
|
-
|
-56.69
|
17.89
|
-9.986
|
-7.172
|
44.21
|
74.15
|
Net margin
|
-
|
-
|
-9,625.3%
|
44.89%
|
-52.42%
|
-33.04%
|
66.6%
|
65.92%
|
EPS
2 |
-2.290
|
-
|
-3.820
|
0.8700
|
-0.4600
|
-0.2850
|
1.790
|
2.955
|
Free Cash Flow
1 |
-
|
-
|
-19.37
|
-
|
-1.112
|
-19.84
|
-12.14
|
8.57
|
FCF margin
|
-
|
-
|
-3,288.62%
|
-
|
-5.84%
|
-91.42%
|
-18.29%
|
7.62%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
11.56%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/09/20
|
11/03/21
|
24/03/22
|
30/03/23
|
08/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.489
|
-
|
-
|
-
|
-
|
39.85
|
1.749
|
3.674
|
11.94
|
1.691
|
1.711
|
3.813
|
3.978
|
10.92
|
EBITDA
|
-3.753
|
-5.67
|
-6.062
|
-4.492
|
-4.044
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.232
|
-6.15
|
-6.508
|
-4.938
|
-4.538
|
34.21
|
-6.131
|
-5.389
|
6.386
|
-5.429
|
-7.708
|
-4.481
|
-4.582
|
5.437
|
Operating Margin
|
-865.44%
|
-
|
-
|
-
|
-
|
85.85%
|
-350.54%
|
-146.68%
|
53.51%
|
-321.05%
|
-450.5%
|
-117.53%
|
-115.19%
|
49.78%
|
Earnings before Tax (EBT)
1 |
-4.23
|
-6.313
|
-6.595
|
-4.927
|
-4.531
|
34.26
|
-5.791
|
-4.961
|
5.575
|
-4.797
|
-7.106
|
-3.958
|
-3.876
|
6.402
|
Net income
1 |
-4.23
|
-6.313
|
-6.595
|
-4.927
|
-4.531
|
33.94
|
-5.791
|
-4.961
|
5.561
|
-4.795
|
-7.106
|
-3.958
|
-3.876
|
6.402
|
Net margin
|
-865.03%
|
-
|
-
|
-
|
-
|
85.17%
|
-331.1%
|
-135.03%
|
46.59%
|
-283.56%
|
-415.31%
|
-103.82%
|
-97.43%
|
58.62%
|
EPS
2 |
-0.2500
|
-0.1800
|
-0.3500
|
-0.2500
|
-0.2200
|
1.690
|
-0.2800
|
-0.2400
|
0.2500
|
-0.2100
|
-0.2900
|
-0.1600
|
-0.1550
|
0.2650
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
24/03/22
|
13/05/22
|
12/08/22
|
04/11/22
|
30/03/23
|
15/05/23
|
11/08/23
|
13/11/23
|
08/03/24
|
10/05/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-19.4
|
-
|
-1.11
|
-19.8
|
-12.1
|
8.57
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/09/20
|
11/03/21
|
24/03/22
|
30/03/23
|
08/03/24
|
-
|
-
|
-
|
Last Close Price
1.685
USD Average target price
19.33
USD Spread / Average Target +1,047.38% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.02% | 44.43M | | +32.09% | 694B | | +29.39% | 593B | | -1.34% | 371B | | +20.34% | 331B | | +7.39% | 290B | | +14.25% | 239B | | -3.03% | 209B | | +10.02% | 209B | | +8.49% | 169B |
Other Pharmaceuticals
|